Product News

Share this article:

GlaxoSmithKline submitted follow-up data and information to the FDA for Cervarix, the company's cervical cancer drug. Cervarix would become the second HPV vaccine on the market in the US, competing with Merck's Gardasil. GSK submitted data from its phase 3 trials, HPV-008. FDA had already reviewed interim data from the same trial, and requested more information. GSK expects FDA's review of Cervarix's biologics license application to take six months.

 

Novartis announced FDA's approval of Afinitor, a kidney cancer drug. Afinitor is indicated for patients with advanced renal cell carcinoma, after failure of treatment with sunitinib or sorafenib.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.